Compare GSK plc (GSK) vs MakeMyTrip Ltd (MMYT) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

MakeMyTrip (MMYT) trades at $54.47, down 2.3% on the day amid a broader bearish technical signal. The company shows strong profitability fundamentals with a 73.77% gross margin and consistent earnings beats in recent quarters, though valuation metrics appear elevated with a P/E of 153.56. Recent news highlights stock volatility tied to travel sector pressures, while analyst consensus remains strongly positive with 8 buy ratings.

The outlook balances robust fundamental execution against high valuation and technical headwinds. Investment opportunity centers on continued market share gains in India's travel sector and margin expansion, while risks include travel demand sensitivity, competitive pressures, and the stock's premium pricing relative to earnings growth.